Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirarubicin for Prevention of Bladder Recurrence in UTUC
NCT02740426Phase 2Unknown
- Sponsor
- Peking University First Hospital
- Start
- Aug 2016
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of pirarubicin in bladder cancer, sponsored by Peking University First Hospital. Status: unknown.
02
Drugs
pirarubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02740426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740426.